Depression treatment for Lantana — the full escalation pathway, 18 minutes away.

RECO Integrated Psychiatry is 11 miles from Lantana — roughly 18 minutes down Federal Highway or A1A from Hypoluxo Island and Manalapan. For clients whose antidepressant history is a list of unfinished or under-dosed trials, RECO offers a documented pharmacologic algorithm, first-line augmentation with aripiprazole, lithium, or T3, and a named escalation option at the end of trial two: rTMS delivered at 120% of motor threshold for 3,000 pulses per session, or Spravato under REMS in-office monitoring.

Lantana sits along the Intracoastal between Delray Beach and West Palm, a short run south on Federal Highway or slightly quicker on A1A past Manalapan and Ocean Ridge. For residents of Hypoluxo Island, Old Town Lantana, and the barrier-island communities immediately north of Boynton Inlet, RECO Integrated Psychiatry provides the closest specialist-level outpatient depression treatment north of Broward — including rTMS, Spravato, and the full pharmacologic escalation pathway for treatment-resistant major depressive disorder.

The diagnostic questions primary care doesn’t ask

The label “depression” is often applied in primary care after a positive PHQ-9 and a brief clinical interview — a workflow that works for uncomplicated first-episode illness but repeatedly misses conditions that mimic unipolar depression. A structured psychiatric intake begins with bipolar spectrum screening using the MDQ and HCL-32, because antidepressant monotherapy in unrecognized bipolar disorder induces mixed states, precipitates rapid cycling, and destabilizes patients who then present months later on their third or fourth medication with the same complaint.

Thyroid dysfunction, iron deficiency, obstructive sleep apnea, undertreated OCD (screened with the YBOCS), PTSD, adult ADHD (ASRS), and stimulant or alcohol use disorders all present with anhedonia, low energy, and disturbed sleep that satisfy DSM-5-TR criteria without being major depressive disorder. The initial evaluation at RECO is structured to catch these misdiagnoses at intake — before a client accumulates four or five failed antidepressant trials that were never going to work because the underlying diagnosis was wrong.

First-line pharmacotherapy done well

For a confirmed unipolar major depressive episode, an SSRI (sertraline, escitalopram, or fluoxetine) or an SNRI (venlafaxine XR, duloxetine) is initiated at a standard starting dose and titrated to a therapeutic dose within two to four weeks. Response is judged at six to eight weeks on a therapeutic dose — not at three weeks on a starting dose, which is where a large share of partial trials get abandoned before they had a chance to work.

Bupropion XL is the first-line option for clients whose profile — SSRI-induced sexual dysfunction, weight gain, sedation, or ADHD comorbidity — argues against a serotonergic agent. Mirtazapine is appropriate for insomnia-predominant presentations and for older clients where modest appetite gain is clinically useful. Every trial is documented with drug, dose, duration, and PHQ-9 trajectory, because those are the data points insurance requires when authorizing later escalation to TMS or Spravato, and the data points that scattered treatment histories almost never contain.

Augmentation and switching after partial response

Partial responders — a meaningful but incomplete PHQ-9 reduction, typically a 25-50% drop from baseline — are augmented before the antidepressant is switched. Augmentation options with the strongest evidence and clearest dosing are aripiprazole (2-15 mg), lithium targeted to a serum level of 0.4-0.8 mEq/L for augmentation rather than the higher levels used in bipolar maintenance, and triiodothyronine (T3) at 25-50 mcg. Quetiapine XR (150-300 mg) and the olanzapine-fluoxetine combination are additional FDA-supported options when a second-generation antipsychotic is clinically appropriate.

Bupropion added to an SSRI is a reasonable augmentation when residual anergia, hypersomnia, or SSRI-induced sexual dysfunction dominate the remaining symptoms. Buspirone augmentation has weaker evidence and is reserved for specific anxious-depressed presentations. For non-responders — no meaningful PHQ-9 change on an adequate trial — the evidence for within-class switching (one SSRI to another) is limited, and a cross-class switch to an SNRI or to bupropion has stronger empirical support. Every decision is anchored to the documented trial, not to intuition or to what the last prescriber happened to prefer.

The interventional escalation pathway

After two adequate antidepressant trials at adequate dose and duration, the client meets consensus criteria for treatment-resistant depression, which is also the coverage threshold for repetitive transcranial magnetic stimulation (rTMS) and for esketamine (Spravato) under most commercial plans. RECO’s protocol names the escalation option at the end of trial two — not at trial four or five — so that failed pharmacology becomes a documented pathway rather than an accumulating series of disappointments.

rTMS is delivered at 120% of motor threshold, typically 3,000 pulses per session over the left dorsolateral prefrontal cortex, five days per week for six weeks. It is the preferred escalation for clients who cannot tolerate additional medication burden or who prefer a non-pharmacologic intervention; scalp discomfort and mild headache are the common side effects and seizure risk sits well below 0.1% per course. Spravato is delivered under REMS in-office monitoring and provides a rapid-response option for clients where the timeline matters — a severe depressive episode, active suicidal ideation with a safety plan, or an occupational deadline that six weeks of TMS cannot accommodate. IV ketamine is available as a cash-pay option for compressed schedules or clients without commercial coverage for esketamine.

What to expect on your first visit

The initial psychiatric evaluation runs 60-75 minutes with the psychiatrist. Records — prior medication trials, hospitalization history, PCP labs including TSH and CBC, and any therapy notes — are requested in advance so the diagnostic interview does not repeat work already done. The visit produces a documented DSM-5-TR diagnosis, baseline PHQ-9 and GAD-7 scores, a written treatment plan with a named first-line agent and target dose, and a follow-up scheduled at two to four weeks for early titration.

Clients continuing therapy elsewhere are supported without disruption; those who want combined medication management and evidence-based psychotherapy are referred to CBT, behavioral activation, ACT, or interpersonal therapy providers, either in-house or in the community. Depression treatment at RECO is not a package — it is a documented algorithm executed one visit at a time.

Insurance and admissions from Lantana

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS, and benefits are verified before the first visit so out-of-pocket costs are known in advance. TMS and Spravato require prior authorization; RECO’s admissions team prepares the prior-auth packet using the pharmacology documentation from earlier trials — one of the reasons documented antidepressant trials matter beyond the immediate clinical decision.

From Lantana, the drive to RECO’s Delray Beach office is 11 miles and roughly 18 minutes down Federal Highway; from Hypoluxo Island, Manalapan, or Ocean Ridge, A1A along the coast is a comparable drive and often faster during season. Same-week initial evaluations are typical, and TMS and Spravato inductions are scheduled as soon as benefits and authorizations are confirmed.

Serving residents of: Hypoluxo Island, Manalapan, Ocean Ridge, Old Town Lantana.